Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.
F I G U R E 1 ALK fusion genes reported in NSCLC. All fusion genes contain ALK exons 20-29 which include the tyrosine kinase domain. Fusion exons indicate the exons at which the breakpoints/fusion of each gene occur, for example E13; A20 indicates a fusion between EML4 exon 13 and ALK exon 20. V1 is the most common fusion in NSCLC followed by V3 and V2. HIP1 = Huntingtin-interacting protein 1; KIF5B = kinesin family member 5B; KLC1 = kinesin light chain 1; TPR = translocated promoter region, nuclear basket protein; BIRC6 = baculoviral inhibition of apoptosis protein repeat containing 6; TFG = TRKfused gene; SEC31A = SEC31 homolog A, COPII coat complex component; DCTN1 = dynactin subunit 1; SQSTM1 = sequestosome 1 such as younger age, light or never smoking history. 1, 4, 5 Furthermore, with rare exceptions, the ALK rearrangement is typically found in adenocarcinoma and tends to be mutually exclusive with other oncogenic drivers, such as EGFR and KRAS mutations. 4, 6, 7 Chromosomal rearrangements of ALK result in a fusion oncogene in which the tyrosine kinase domain (KD) of ALK comes under the control of the promoter of a different gene ( Figure 1 ) leading to ligand independent constitutive activation of the tyrosine kinase and its downstream signaling pathways (Figure 2 ). 8 The most common rearrangement is with echinoderm microtubule-associated protein-like 4 (EML4)-due to a chromosomal inversion within the short arm of Chromosome 2 1 ; however, rearrangements can also occur with a number of different genes ( Figure 1 ). 1, 9 Identification of an ALK rearrangement is a key as it confers sensitivity to treatment with ALK tyrosine kinase inhibitors (TKIs; ALKi).
The use of these inhibitors has resulted in major clinical advances ALK copy number gain (CNG) or the emergence of bypass pathway signaling. 10, 11 Identifying the various resistance pathways is critical to developing new treatment strategies and overcoming acquired resistance.
OBJECTIVE
The landscape of treating ALK-rearranged NSCLC is rapidly evolving.
The objective of this review is to provide a summary of the current treatment approach to ALK-rearranged NSCLC, highlighting the therapeutic challenges in the context of current literature evidence and the Australian context.
METHODS
A comprehensive literature review was performed in Embase, Medline, Premedline and Cochrane databases, in addition to ClinicalTrials.gov and WHO. 12, 13 The terms "ALK" or "anaplastic lymphoma kinase" adjoining "positive" or "rearranged" or "re-arranged" or "translocated"; attached with "carcinoma," "non-small cell lung" or "non-small cell" or "adenocarcinoma" referenced anywhere within the title or article were grouped further with "lung" or "lung neoplasm" thus, to capture all pertinent articles in the both preclinical and clinical setting. Results were not filtered for date or language.
At data search update (May 31, 2017): 668 articles were identified in Medline; 640 via Embase; 44 in Premedline and 15 Cochrane review articles. There was considerable article overlap interdatabase. Articles relevant to the topic were selected manually via the search strategy results.
F I G U R E 3
Comparison of routine diagnostic assays for ALK NSCLC: (A) FISH analysis of a lung adenocarcinoma sample showing cells with an ALK translocation using a break apart probe. In this method, two differently colored probes (red and green) flank the highly conserved translocation breakpoint within ALK. Separation of the probes due to an ALK rearrangement results in separation/splitting of the red and green signals in the affected chromosome (dashed arrows). In the other normal chromosome, the overlying red and green probes result in a yellow (fused) signal (solid arrow); (B) an example of ALK IHC (variant 1) positive staining. IHC involves selectively imaging antigens (in this case, ALK protein) in cells of a tissue section using specifically designed antibodies. Tissue sections are scored positive if strong granular cytoplasmic staining (dark brown color) in tumor cells is present; (C) RT-PCR: in RT-PCR, RNA is reverse transcribed (RT) to complementary DNA (cDNA) prior to amplification by polymerase chain reaction (PCR) with primers flanking the breakpoint and fusion. A product will be obtained only if that particular fusion gene is present. *Sensitivity and specificity of the different techniques were compared in Ref. 85 ; benefits/cost compared in Ref. 86 
DISCUSSION

Detection of ALK-rearranged NSCLC
ALK gene rearrangements or the resulting fusion proteins may be detected in tumor specimens using fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), reverse transcription polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS). 14 ALK break-apart FISH assays remain the gold standard due to their high sensitivity and specificity in identifying ALK rearrangements and it is mandated for clinical trial inclusion ( Figure 3) . 15, 16 High-sensitivity ALK IHC with next-generation antibody clones (such as 5A4 and D5F3) has performed more favorably than first anticipated, due to its relative accessibility and rapid-throughput method, high-sensitivity (up to 100%) and cost-effectiveness. 17 In the clinical setting, many centers in Australia now routinely screen all cases of nonsquamous NSCLC for ALK gene rearrangement by IHC followed by confirmatory FISH testing only in ALK IHC cases. 18 Neither FISH nor IHC can identify the fusion partner. However, the exact clinical relevance of different fusion partners is not well characterized.
The identification of both the ALK rearrangement and a fusion partner is possible by RT-PCR and NGS technologies and RT-PCR was a commonly used screening strategy for detecting the most frequent ALK gene fusion partners. Assays have been designed for particular ALK fusions, which, while 100% specific for these fusions, are unable to detect novel fusion partners. Each newly identified fusion thus requires a new assay, making testing uneconomical and this testing strategy is no longer recommended. In addition, it can be difficult to obtain highquality RNA from routine formalin fixed paraffin embedded tissue and RT-PCR is not currently recommended by the CAP/IASLC/AMP guidelines to select patients for ALK-TKI treatment. 19 The ability of targeted NGS to economically sequence large amounts of DNA and identify structural variations may see this testing introduced more routinely in the future for the identification of both known and novel ALK arrangements. 20 
Efficacy and safety of ALK inhibitors
First-generation ALK inhibitor -crizotinib
Crizotinib is an oral small-molecule TKI targeting ALK, MET and ROS1 tyrosine kinases. 21 In two single-arm studies, crizotinib showed marked antitumor activity in patients with advanced ALK-positive NSCLC, with an ORR of approximately 60%. 22 In 2013, the first randomized control phase III trial, PROFILE 1007, confirmed the benefit of crizotinib over conventional second-line chemotherapy with a median (m)PFS of 7.7 versus 3 months (Table 1) .
Symptom burden of cancer and quality of life were also improved. 
Second-line treatment in crizotinib refractory disease
Second-generation ALK inhibitors have generally been shown to have potent clinical activity, with actions against several crizotinibresistant ALK KD mutations and improved CNS penetration. 26 Secondgeneration ALKi were first clinically evaluated in the second-line setting with substantially longer mPFS results than seen with chemotherapy (Tables 1 and 2 ). 27 Ceritinib was the first second-generation ALKi to show efficacy with reports of a 20-fold greater potency than crizotinib in enzymatic assays. 26 In the updated large phase I ASCEND-1 study in pretreated patients, ORR was 72% and mPFS was 8.9 months, while in the phase II ASCEND-2 trial PFS was 5.7 months. CNS activity was superior to crizotinib. 27, 28 In enzymatic assays, alectinib is approximately five times more potent than crizotinib. 29 In contrast to the other TKIs, alectinib does not inhibit the kinase activity of MET or ROS1. In the pivotal phase II trial, ORR in crizotinib refractory patients was 49% and mPFS was 8.9
months. 30 Early-phase brigatinib data in a pretreated population have also been promising. Preclinical activity has been demonstrated in patients with KD mutations conferring resistance to crizotinib, ceritinib and alectinib. 31 The updated ALTA trial reported a 15.6-month mPFS after crizotinib and an ORR of 62%. 32 Entrectinib is a novel potent oral TKI with activity against patients with ALK in both the naïve and pretreated setting also reported. 33 Phase I data have demonstrated the safety and efficacy to carry this drug forward in trial as it has also demonstrated activity against a panel of resistance mutations. 34 The first-line brigatinib ALTA-1L trial versus crizotinib has now closed to recruitment and results are awaited (NCT02737501). Earlyphase data reported a confirmed ORR of 62% in crizotinib pretreated patients and 100% in the crizotinib naïve population. 38 The global phase III (eXalt3) is now recruiting, comparing entrectinib to crizotinib as first-line therapy (NCT02767804).
Several differences between the studies exist including patient baseline demographics and disease status as well as inclusion criteria exist that do not allow for direct comparison (Tables 1 and 2 ).
Toxicity of second-generation ALK inhibitors
The second-generation ALKi differ in their side effect profiles. Ceritinib is associated with diarrhea in 85%; however, ≥ grade 3 occurs in only 5%. 35 One suggested strategy is to introduce therapy at a lower than recommended dose and titrate up to mitigate gastrointestinal (GI) toxicity and raised transaminases. Alectinib is generally well tolerated with myalgias, grade 1-2 GI toxicity and fatigue the most frequently reported toxicities. 30 Brigatinib has been found to induce an idiopathic elevation in creatine kinase and lipase and reports of an early, steroid responsive, pneumonitis. To alleviate this, the phase III first-line trial introduces brigatinib at a lower dose before dose escalation in the absence of symptoms. 38 Entrectinib is generally well tolerated, with low-grade fatigue, dysgeusia, parasthesias and nausea being most common. 34 These toxicities may direct switch to an alternate ALKi if dose interruption, delay or pre-emptive/supportive treatment do not permit their ongoing use.
Third-generation ALK inhibitor -lorlatinib
The safety and efficacy of lorlatinib has been established in the earlyphase setting in treatment naïve and pretreated patients including those with CNS disease.
Preclinical data with lorlatinib revealed that it is potent against ALK fusions and inhibits recognized KD mutations including the G1202R which infers resistance to prior ALKi. 39 The mOS in second-line treatment was 13.5 months. Intracranial ORR was 39% with the CSF to serum ratio 0.61-0.96. Further durable efficacy has been reported in leptomeningeal disease. 40 The spectrum of lorlatinib toxicity reported to date includes uncomplicated hypercholesterolemia, hypertriglycerolemia, peripheral edema and reversible peripheral neuropathy. 40 A phase III study of lorlatinib versus crizotinib in first-line treatment of patients with ALK+ NSCLC is now recruiting (NCT03052608). 
Central nervous system disease in ALK NSCLC
CNS disease in crizotinib-treated patients
Crizotinib penetration into CSF is negligible (0.3% of plasmatic concentration). 42 Yet, retrospective pooled analysis of the PROFILE 1005 and 1007 revealed median intracranial time to progression (TTP)
in previously untreated CNS disease with crizotinib of 7 months and in those with prior treatment for brain metastases 13.2 months. 43 Prospective data in the PROFILE 1014 trial revealed that crizotinib was superior overall to chemotherapy in patients with treated brain metastases (mPFS of 9 vs 4 months; R 0.40; P<0.001). 41 Prior targeted treatment of CNS with radiotherapy (RT) therefore improves the PFS on crizotinib; however, patients can still derive clinical benefit without pretreatment. Better CNS penetration of systemic ALK targeted treatments is needed for patients with CNS disease from ALK+ NSCLC.
CNS disease in second-generation ALKi patients
Newer generation ALKi have demonstrated superior CNS efficacy and given their improved penetration of the CNS, inclusion criteria for trials have not generally required pretreatment with RT for asymptomatic CNS metastases.
Ceritinib has demonstrated CNS concentrations with a brain to blood exposure ratio in mouse models of 15%. 44 Disease control in the brain was achieved in 79% of patients with pretreated CNS metastases. 27 Despite this, in the first-line trial, 48% of patients with pre-existing brain metastases and 30% of those-without baseline CNS disease still progressed in the brain. MPFS for those with baseline brain metastases was 10.7 months. First-line ceritinib CNS ORR was 46.3%, with no significant difference in those pretreated with RT. 35 In patients on second-line alectinib CNS, ORR was 57%; 10 of 23 patients who had not had prior RT had a CNS complete response.
In the first-line setting, five patients with CNS metastases at baseline treated with alectinib had CSF drug concentrations approximating unbound systemic concentrations. 45 The updated J-ALEX first-line alectinib data found that alectinib also prevented CNS progression The brigatinib CNS data reported to date are encouraging with ORR of 53% in patients not treated with prior RT and 56% in those who received previous CNS RT. 38 The incidence of leptomeningeal carcinomatosis in ALK-rearranged NSCLC is unknown; however, it is expected to be higher than the prior reported incidence of 5% in NSCLC. 47 This is likely multifactorial beyond CNS tropism, as imaging techniques have improved; and MRI of the brain now routine thus arguing for historical underreporting; therapeutic drug concentration in CSF is difficult to achieve; and patients are living longer. 48 An intriguing case report found that dose escalation above the recommended phase II dose (RP2D) of alectinib to 900 mg BD achieved an objective and durable response in a patient with leptomeningeal disease. 49 The use of next-generation ALKi can be seen as an RT-sparing measure. Despite advances in treatment and survival, outcomes remain inferior to those in patients without CNS disease. Tumor genotyping of brain metastases may assist our further understanding of biological and molecular factors predicting for CNS relapse and progression.
Resistance to ALK inhibitors 4.4.1 Resistance to crizotinib
Unfortunately, some patients do not respond initially to crizotinib and acquired drug resistance inevitably develops in those who do respond.
The mechanisms mediating such resistance have been described and our understanding continues to evolve with ongoing treatment advances ( Figure 4) . 10 
ALK-dependent crizotinib resistance
Different ALK fusion genes may have differing sensitivities to crizotinib with EML4-ALK variant 1 reported to have greater sensitivity than other EML4-ALK variants. 9 Beyond this, the development of ALK KD mutations can block the binding affinity of crizotinib as well as other TKIs and increase protein kinase activity. 51 These mutations are thought to account for approximately 25% of cases of crizotinib resistance. The gatekeeper L1196M mutation is the most common, characterized in approximately 30% of cases. 52 Other mutations which confer variable levels of resistance have also been described, such as G1202R, G1269A and S1206Y. Some mutations such as C1156Y and L1152R confer resistance by allosteric hindrance of the binding site, decreased affinity for crizotinib or interference with downstream signaling phosphorylation. As described in subsequent sections, second-generation ALKi have differing activities in the presence of the known KD mutations as the frequency of these mutations increases with each line of ALKi. [53] [54] [55] [56] Amplification/CNG of the ALK fusion gene, alone or combined with secondary mutations, is responsible for the development of secondary resistance after crizotinib therapy in < 20% of cases. It is thought to allow for downstream signaling despite partial inhibition by crizotinib. 10
ALK-independent crizotinib resistance
Bypass signaling can also occur with the activation of, and constitutive signaling through, other pathways which have been increasingly described as resistance mechanisms to crizotinib. Activation of the EGFR pathway in this context usually occurs through increased phosphorylation and upregulation of ligands. 57 Rarely, concomitant activating EGFR and KRAS mutations have also been described, possibly reflecting the emergence of pre-existing clones under selective pressure from crizotinib. 57, 58 Transformation to small cell lung cancer has been described in a patient who was treated with crizotinib and alectinib. 59 Pharmacologic mechanisms such as inadequate penetration into the CNS may also produce therapeutic resistance. 42 Tissue and blood-based biomarkers are being developed and validated to test for the heterogeneous and dynamic ALK dependent and independent mechanisms of resistance. Currently, in 25% of cases, the cause for resistance remains unknown. An attempt to obtain repeat tissue or liquid biopsy upon progression is recommended especially as NGS testing is becoming increasingly available and less expensive ( Figure 4 ). 60-62
Resistance mechanisms to next-generation inhibitors
Apart from improved CNS penetration of next-generation ALKi, alternative resistance mechanisms have been demonstrated. There have been more than 17 KD mutations conferring resistance to firstgeneration and/ or next-generation ALKi described to date. 31, 63 The frequency of these mutations increases with each line of therapy as the sensitivity to different ALKi varies. For ceritinib, I1123S, L1152R, F1174C/V and G1202R have been identified clinically as resistance mutations. 64 For alectinib, I1171N/T/S and G1202R produce resistance 65 ; while brigatinib is ineffective in the presence of G1202R. 31, 64 For alectinib, I1171N/T/S and G1202R confer resistance 65 ; while brigatinib is G1202R sensitive. 31 Lorlatinib has demonstrated pan inhibitory activity against the known KD mutations apart from L1198F which paradoxically maintains crizotinib sensitivity. 40 Although demonstration of the presence of specific ALK mutations could establish the sequence of treatment with various ALKi, mechanisms other than mutations in ALK drive crizotinib resistance in most tumors. Therefore, the ALK-independent mechanisms highlighted in Figure 4 relate predominantly to resistance to the next-generation TKI.
Treatment beyond progression and managing oligoprogressive disease
The PROFILE trials permitted treatment beyond RECIST progression if prior disease control had been achieved in those still deriving clinical benefit. 23, 25 Local aggressive therapy of both CNS and extra-cranial disease and ongoing crizotinib therapy were also allowed. In the PRO-FILE 1001 and 1005 trials, 62% of patients who had progressed at data cut off remained on crizotinib. In patients who were treated beyond progression, the mOS from the time of PD in those who continued crizotinib was 16.4 versus 3.9 months (P<0.0001). 66 This concept is supported scientifically as NSCLC represents a complex genomic landscape. Intratumoral and intertumoral heterogeneity and treatment selection pressure drive clonal diversity fueling drug resistance. 67 Further challenges arise in CNS only progression given drug delivery is suboptimal with crizotinib. Continuation of targeted therapy when there is no systemic progression after local CNS therapy has proven beneficial. 68 Treating a resistant clone with ablative therapy before widespread dissemination may prolong disease control until either a new event occurs or resistant clones that have disseminated expand sufficiently to become detectable. Targeted therapy can continue to be of benefit in other sites of nonprogressing disease because of continuing suppression of sensitive clones that have not yet developed acquired resistance. A retrospective series has demonstrated that this approach can extend systemic treatment benefit by 6 months. 69 Switching therapy at disease progression while concurrently managing the dominant progressing lesion with aggressive local therapy has been reported to potentially enhance an ongoing durable systemic therapy benefit. 70 Therefore, in clinical practice, where there is the presence of "oligoprogressive disease," for example CNS, local ablative therapy with the continuation of existing systemic therapy may be a viable approach in selected patients. However, an immediate change of therapy should be the preferred strategy in patients with significant and symptomatic progression.
Use of immunotherapy in ALK NSCLC
At present, there is no evidence to support the use of single-agent immunotherapy in ALK-rearranged NSCLC. The phase III CheckMate-057 included only three patients with ALK rearrangements; however, there were 53 cases with EGFR mutations in which there was a trend to improved efficacy with docetaxel chemotherapy. 71 The equivalent phase II/III KeyNote 010 trial with pembrolizumab yielded the same finding. 72 The lack of benefit was also seen in nonsmokers who represent a great proportion of those with ALK rearrangements. Clinical trials have since excluded patients with ALK rearrangements.
PD-L1 expression is, however, found to be upregulated by the EML4-ALK by activating downstream PI3K-AKT and MEK-ERK signaling pathways. 73 A small series has found that PD-L1 expression is five times higher in ALK translocated patients than in wild-type patients. 74 Studies are underway to review combination therapies encompassing immunotherapy. Early data from a phase I dose escalation trial of ceritinib with nivolumab have demonstrated activity; however, the toxicity profile warrants review before further investigation (NCT02393625). 75 
Treatment sequencing of ALK inhibitors
It remains unknown how to best sequence ALKi therapy. Therapeutic decision making to date has been dictated by phase III clinical trial In the PROFILE 1007 study, mOS in patients who crossed over to crizotinib from chemotherapy from the time of cross-over was 20 months, which was far superior to prior NSCLC reports. 25 Retrospective real-world data are becoming available on the experience with treatment sequencing. One such report of 73 patients treated with crizotinib followed by ceritinib produced a combined mPFS of 17.4 months. 76 A similar small series investigated crizotinib with alectinib in only 11 patients and delivered a comparable combined mPFS of 18.2 months. 23, 77 An Italian series reported an ORR with second-line ALKi of 86.4%, analogous with clinical trial data. 78 The most impressive experience to date is from a large retrospective French series of 318 patients treated with crizotinib in different lines that found in 84 patients who went on to receive a next-generation ALKi, a median postcrizotinib progression OS of 25.0 months and mOS for all patients of 89.6 months. 79 As is our experience with next-line treatment across tumor types, early-phase lorlatinib data revealed an attenuated response to lorlatinib when utilized in the third-line versus second-line setting (mPFS 9.2 months compared to 13.5 months). 40 Whether to use this most potent ALKi upfront or to reserve it is a question requiring further exploration. Patient factors such as performance status and tumor burden may further guide this decision, as reserving drug may not be beneficial for all. 80 Recent data from the first-line second-generation ALKi alectinib phase III trial revealed that alectinib-treated patients had not reached mPFS after 18.6 months follow-up. It is predicted to surpass the cumulative mPFS (across trials) for first-generation crizotinib with secondgeneration TKIs in the second-line setting offering a compelling argument to utilize the most potent ALKi upfront. 46 
FUTURE DIRECTIONS
Importance of repeat biopsies for the emergence of drug resistance
Understanding the temporal genetic changes influencing drug resistance may guide the selection of further tailored treatments in those patients affected. It is widely encouraged and accepted that tumor biopsies need to be performed at the time of disease progression if feasible. The risks and benefits of rebiopsy have been discussed and supported in the literature and are of pivotal importance in ALK+ NSCLC. 81 The recent landmark case report of an ALK+ NSCLC patient who had multiple repeat biopsies at tumor progression to potentially guide therapy emphasizes the value of repeat biopsy. 82 Thirty-six months into treatment, the patient developed a new KD mutation (L1198F) implying lorlatinib resistance. Remarkably, the patient was rechallenged with crizotinib and achieved durable response despite prior resistance. 82 It remains unclear if a particular sequence of ALKi influences the emergence of specific resistance mechanisms, and therefore the clinical course of the patient. Therefore, the question of the most appropriate sequence of ALKi for the individual patient can only be answered by trials such as the proposed ALK MATCH trial, a concept similar to the ongoing NCI-MATCH trial identifying genomic drivers in cancer in order to develop more effective treatment approaches (NCT02465060).
Liquid biopsies for less-invasive identification of mechanisms of resistance
Plasma circulating free DNA (cfDNA) enabling mutational profiling may be a less-invasive, easily accessible tool for the detection of molecular changes and ALK rearrangements, including secondary mutations. 60 This could be used to identify impending resistance mechanisms thereby facilitating early treatment change and optimal ongoing therapeutic choice although this approach requires further prospective studies to confirm utility.
The challenge of using cfDNA for ALK is similar to those described above where PCR amplification of the target sequence is needed to detect the rearrangement. Currently, this requires either developing an individualized assay for each breakpoint or using a predesigned assay with multiple breakpoints.
Reports on sensitivity and concordance with liquid assays compared to tissue biopsy have been published as a validated commercial assay for "liquid biopsy" is yet to be available. 61 Circulating tumor cells (CTCs) may also represent a noninvasive and easily accessible source of tumor material for assessing predictive molecular biomarkers and screening patients eligible for targeted treatments. Recently, a modified FISH assay with filtration enrichment (FA-FISH) was developed to identify ALK rearrangements using CTC in ALK, which may allow for a diagnostic and monitoring presence in the future as a noninvasive predictive biomarker. 83 With increasing accessibility and cost-effectiveness, NGS is predicted to become the gold standard of resistance testing in both solid and liquid samples in ALK.
Accessibility of ALKi
The predicted economic cost in facilitating the availability of multiple ALKi in the clinic, as well as companion diagnostic panels, is a further pivotal consideration which will influence how we manage ALK NSCLC in the future. Not only is our management directed by the updated literature, but also our ability to access treatment.
Adjuvant ALKi
Investigation is ongoing into the efficacy of ALKi over chemotherapy in the adjuvant setting. The ALCHEMIST trial of crizotinib in patients with stage IB-IIIA-resected NSCLC is currently recruiting (NCT02201992).
There has been a suggested disease-free survival benefit of TKI therapy (gefitinib) in a preceding trial in the EGFR adjuvant setting, with OS data awaited. 84 
CONCLUSIONS
The treatment landscape in ALK-rearranged NSCLC has rapidly progressed over the past decade and continues to evolve. The evidence for current management is based around pivotal phase III clinical trial data. However, with multiple drugs and multiple trials, many questions remain regarding the optimal therapy and drug sequence. 
